title: Assessing the New and Emerging Treatments for Atopic Dermatitis.
abstract: The newer and emerging treatments for atopic dermatitis (AD) focus on blockade of inflammatory cytokines, especially those that derive from T helper cell type 2 (TH2) and are associated with a pathway of immunoglobulin E (IgE) sensitization. Among the proinflammatory cytokines that have been identified as promising therapeutic targets are chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2), IgE, thymic stromal lymphopoietin (TSLP), and several monoclonal antibodies that block key cytokine pathways in the innate immune response. Two agents that have been studied in phase III clinical trials are the boronbased phosphodiesterase-4 (PDE-4) inhibitor, crisaborole, and dupilumab, an antibody that inhibits the interleukin-4/ IL-13 receptor α chain. Semin Cutan Med Surg 35(supp5):S92-S96.
authors.affiliation: Professor of Dermatology and Pediatrics Chief, Pediatric and Adolescent Dermatology University of California San Diego School of Medicine Rady Children's Hospital San Diego, California.
authors.forename: Lawrence F
authors.initials: LF
authors.lastname: Eichenfield
authors.affiliation: Professor of Dermatology and Pediatrics University of California San Diego School of Medicine Fellowship Program Director Pediatric and Adolescent Dermatology Rady Children's Hospital San Diego, California.
authors.forename: Sheila F
authors.initials: SF
authors.lastname: Friedlander
authors.affiliation: Professor of Dermatology Director of Clinical Studies Oregon Health and Science University Department of Dermatology Portland, Oregon.
authors.forename: Eric L
authors.initials: EL
authors.lastname: Simpson
authors.affiliation: Professor of Dermatology Trinity College Dublin Attending Dermatologist Our Lady's Children's Hospital Crumlin St. James's Hospital Dublin, Ireland.
authors.forename: Alan D
authors.initials: AD
authors.lastname: Irvine
mesh_terms: D002648:Child; D003876:Dermatitis, Atopic / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D019587:Dietary Supplements; D006801:Humans; D053662:Interleukin-4 Receptor alpha Subunit / Q000037:antagonists & inhibitors; D007378:Interleukins / Q000037:antagonists & inhibitors; D053612:Janus Kinases / Q000037:antagonists & inhibitors; D008550:Melatonin / Q000627:therapeutic use; D058988:Phosphodiesterase 4 Inhibitors / Q000627:therapeutic use; D018121:Receptors, Cytokine / Q000037:antagonists & inhibitors; D014807:Vitamin D / Q000627:therapeutic use
chemical_list: C498762:CRLF2 protein, human; D053662:Interleukin-4 Receptor alpha Subunit; D007378:Interleukins; D058988:Phosphodiesterase 4 Inhibitors; D018121:Receptors, Cytokine; D014807:Vitamin D; D053612:Janus Kinases; D008550:Melatonin
keywords: Atopic dermatitis; crisaborole; dupilumab; interleukin inhibitors; petrolatum; skin barrier